Logotype for Sareum Holdings plc

Sareum Holdings (SAR) investor relations material

Sareum Holdings H1 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Sareum Holdings plc
H1 2025 earnings summary25 Mar, 2025

Executive summary

  • Completed Phase 1 trial for SDC-1801, showing strong safety, pharmacokinetics, and biomarker effects for once-daily dosing in autoimmune diseases, especially psoriasis; no serious adverse events.

  • Regained control and increased economic interest in SRA737 to 63.5% after license return, enabling new development and licensing opportunities.

  • Strengthened patent portfolio for SDC-1801 in the US, China, and Japan, enhancing competitive position.

  • Cash position strengthened to over £4 million at period end, with an additional £1.07 million raised post-period.

  • Operating expenses and loss after tax significantly reduced year-over-year due to lower clinical trial costs.

Financial highlights

  • Cash at 31 December 2024 was £4.1 million, up from £1.5 million at 30 June 2024 and £0.4 million at 31 December 2023.

  • Loss after tax for the six months to 31 December 2024 was just over £1.2 million, improved from £1.8 million (or restated £1.7 million) loss for the same period in 2023.

  • Revenue for the six months ended 31 December 2024 was £22,000; operating expenses were £1.3 million, down from £2.5 million in the prior year.

  • Net assets increased to £4.3 million as of 31 December 2024, compared to £1.2 million at 31 December 2023.

  • Received approximately £1.3 million in investment and R&D tax credit post-period.

Outlook and guidance

  • SDC-1801 aims for Phase 2 readiness by year-end, with long-term toxicology studies scheduled to complete in Q4 2025.

  • SDC-1802 preclinical studies are being accelerated, with manufacturing underway and target cancer selection planned.

  • SRA737 program under review for further commercialization and development, with potential clinical trials and active licensing discussions.

  • Dual strategy for SDC-1801: preparing for Phase 2 trial while exploring licensing opportunities.

  • Continued rigorous capital allocation and readiness to respond to new opportunities in kinase inhibitor therapeutics.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Sareum Holdings earnings date

Logotype for Sareum Holdings plc
H2 202523 Oct, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Sareum Holdings earnings date

Logotype for Sareum Holdings plc
H2 202523 Oct, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Sareum Holdings plc is a UK-based biotechnology company focused on the discovery and development of small molecule therapeutics targeting cancer and autoimmune diseases. The company specializes in kinase inhibition and advances its drug candidates through preclinical and early clinical development stages. Sareum’s lead programs target immune and inflammation pathways, and the company collaborates with partners to support further development and commercialization. Sareum Holdings plc is headquartered in Cambridge, United Kingdom, and its shares are listed on the AIM.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage